Money Talks

BioNTech to develop mRNA-based malaria vaccine | Money Talks

BioNTech aims to develop a more effective vaccine against malaria, one of the world's deadliest diseases. Nearly 230 million people are infected with the mosquito-borne parasite each year. The German firm is now seeking to follow up its successful COVID-19 vaccine, with a malaria jab based on the same messenger RNA technology. If successful, the shot could significantly reduce the mortality rate of the disease. Sibel Karkus has more. #Malaria #BioNTech #mRNA

Picture This: Brussels Attacks Anniversary

Picture This: Brussels Attacks Anniversary

The Newsmakers: America's Anti-Terror Strategy

The Newsmakers: America's Anti-Terror Strategy

The Newsmakers: America's Anti-Terror Strategy and Australia Redefining Racism

The Newsmakers: America's Anti-Terror Strategy and Australia Redefining Racism

Showcase: 'I Am Not Madame Bovary'

Showcase: 'I Am Not Madame Bovary'

Biz in 60

Biz in 60

Biz in 60

Biz in 60

Biz in 60

Biz in 60

Emmy Awards dominated by streaming services | Money Talks

Emmy Awards dominated by streaming services | Money Talks

PM's party wins but misses out on parliamentary majority | Money Talks

PM's party wins but misses out on parliamentary majority | Money Talks

Australia's nuclear submarine deal with US, UK angers France | Money Talk

Australia's nuclear submarine deal with US, UK angers France | Money Talk

Markets slump as major Chinese builder faces default | Money Talks

Markets slump as major Chinese builder faces default | Money Talks

Biz in 60

Biz in 60

Biz in 60

Biz in 60

New York firm operates eco-friendly vessel to ship goods | Money Talks

New York firm operates eco-friendly vessel to ship goods | Money Talks

Bitcoin mining surge worsens global e-waste pileup | Money Talk

Bitcoin mining surge worsens global e-waste pileup | Money Talk

African firms seek more business with Turkish counterparts  |  Money Talks

African firms seek more business with Turkish counterparts | Money Talks

Show More